background
venezuelan
equin
enceph
viru
veev
respons
vee
epidem
occur
south
central
america
us
veev
envelop
contain
two
glycoprotein
mediat
cell
membran
fusion
bind
receptor
elicit
viru
neutral
antibodi
previous
construct
epitop
map
use
murin
monoclon
antibodi
mmab
six
epitop
c
e
f
g
h
bound
veevneutr
antibodi
map
amino
acid
aa
noth
known
human
antibodi
repertoir
veev
epitop
engag
human
virusneutr
antibodi
specif
treatment
vee
howev
virusneutr
mmab
potent
protect
therapeut
agent
mice
challeng
veev
either
peripher
aerosol
rout
therefor
fulli
human
mab
hmab
virusneutr
activ
use
prevent
clinic
treatment
human
vee
method
use
phagedisplay
isol
veevspecif
hfab
human
bone
marrow
donor
hfab
character
sequenc
specif
test
veev
subtyp
crossreact
use
indirect
elisa
vitro
viru
neutral
capac
one
neutral
hfab
convert
igg
bind
site
identifi
use
competit
elisa
mmab
prepar
sequenc
antibodi
neutralizationescap
variant
find
use
veevreact
hfab
construct
first
human
epitop
map
alphavir
surfac
protein
identifi
import
neutralizationassoci
epitop
uniqu
human
immun
respons
use
resolut
cryoelectron
microscopi
map
sindbi
viru
protein
show
probabl
surfac
locat
human
veev
epitop
veevneutr
capac
hmab
nigg
similar
exhibit
human
mmab
igg
igg
shown
limit
veev
infect
mice
prophylact
therapeut
administr
cocktail
igg
bind
differ
epitop
could
provid
enhanc
prophylaxi
immunotherapi
veev
reduc
possibl
gener
possibl
harm
viru
neutralizationescap
variant
vivo
venezuelan
equin
enceph
viru
veev
member
alphaviru
genu
famili
togavirida
maintain
natur
enzoot
cycl
mosquito
rodent
host
although
equin
human
may
also
infect
epizoot
cycl
veev
caus
hightit
viremia
equin
result
enceph
mortal
rate
diseas
human
usual
selflimit
consist
fever
chill
malais
sever
headach
progress
sever
enceph
outbreak
epizoot
veev
subtyp
occur
period
south
central
america
even
spread
south
texa
therefor
consid
emerg
pathogen
last
major
transcontinent
outbreak
epizoot
veev
occur
smaller
south
central
american
outbreak
veev
occur
sinc
one
colombia
venezuela
mid
late
outbreak
caus
usual
enzoot
subtyp
veev
occur
peru
panama
mexican
state
chiapa
oaxaca
veev
potenti
bioweapon
princip
low
human
infect
dose
easi
product
capabl
effect
transmiss
aerosol
list
niaid
categori
b
prioriti
pathogen
experiment
vaccin
use
protect
laboratori
personnel
militari
troop
licens
gener
use
new
liveattenu
vaccin
develop
virul
veev
infecti
clone
sitedirect
mutagenesi
prove
effect
anim
studi
associ
advers
event
phase
clinic
trial
subsequ
abandon
alphavirus
positivesens
singlestrand
rna
genom
approxim
kb
enclos
within
icosahedr
nucleocapsid
surround
lipid
bilay
deriv
infect
cell
plasma
membran
two
integr
membran
glycoprotein
embed
lipid
envelop
assembl
heterodim
trimer
spike
viru
surfac
although
crystal
structur
capsid
protein
sever
alphavirus
solv
welldiffract
crystal
either
viru
particl
obtain
howev
cryoelectron
microscopi
cryoem
reconstruct
sever
alphavirus
report
provid
insight
probabl
structurefunct
relationship
glycoprotein
respons
cell
membran
fusion
primarili
involv
receptor
bind
cell
entri
well
elicit
veevspecif
neutral
antibodi
previous
analyz
antigen
structur
veev
glycoprotein
use
murin
monoclon
antibodi
mab
defin
six
epitop
c
e
f
g
h
involv
veev
neutral
epitop
cluster
critic
veev
neutral
site
map
amino
acid
aa
sequenc
rna
mab
neutralizationescap
veev
variant
similar
neutral
site
identifi
sindbi
viru
sv
ross
river
viru
rrv
use
mmab
veev
epitop
c
h
conserv
glycoprotein
heterolog
veev
specif
treatment
veev
infect
avail
howev
mab
react
critic
neutral
site
demonstr
potent
protect
activ
murin
model
follow
either
peripher
aerosol
challeng
virul
veev
moreov
c
mmab
g
mmab
well
human
c
mmab
igg
shown
provid
postexposur
protect
administ
within
hr
viru
inocul
fulli
human
h
mab
would
best
choic
clinic
treatment
human
infect
howev
littl
known
immunolog
specif
human
antibodi
repertoir
veev
protect
hmab
yet
isol
character
implement
report
present
map
human
veev
antibodi
respons
determin
human
immunodomin
epitop
veev
protein
use
phagedisplay
technolog
isol
veevspecif
hfab
bone
marrow
donor
known
circul
antibodi
veev
character
panel
hfab
veev
surfac
protein
specif
subtyp
crossreact
vitro
virusneutr
capac
two
hfab
one
exhibit
potent
neutral
activ
convert
fulli
human
molecul
two
hmab
neutralizationescap
veev
variant
isol
sequenc
protein
gene
variant
virus
identifi
uniqu
human
veev
neutral
domain
like
bind
site
hmab
alphaviru
cryoem
map
associ
marker
support
propos
probabl
surfaceaccess
locat
veev
nativ
n
igg
bind
site
vee
complex
virus
use
studi
trinidad
donkey
trd
subtyp
varieti
ab
vaccin
strain
mena
ii
everglad
eve
mucambo
muc
pixuna
pix
cabass
cab
rio
negro
obtain
divis
vectorborn
infecti
diseas
dvbid
center
diseas
control
cdc
fort
collin
co
virus
grown
vero
cell
purifi
equilibrium
densitygradi
centrifug
purifi
veev
use
pan
phage
display
librari
inactiv
bpropiolacton
bpl
tri
base
ph
h
viru
inactiv
verifi
inocul
vero
cell
monitor
cytopath
effect
cpe
inactiv
viru
evalu
elisa
preserv
import
epitop
reactiv
neutral
mmab
antiveev
neutral
mmab
respect
neutralizationescap
variant
virus
use
character
hmab
nigg
welldocu
total
rna
obtain
bone
marrow
blood
sampl
suppli
two
militari
donor
use
trireag
bd
molecular
research
center
inc
cincinnati
oh
accord
manufactur
instruct
blood
util
project
obtain
protocol
approv
scripp
clinic
irb
assur
number
bone
marrow
sampl
obtain
commerci
sourc
donor
sera
elisa
titer
veev
messeng
rna
isol
use
oligotex
spin
column
qiagen
valencia
ca
follow
manufactur
protocol
amplifi
mrna
first
strand
cdna
synthes
use
superscript
ii
revers
transcriptas
invitrogen
carlsbad
ca
although
murin
immun
respons
venezuelan
equin
enceph
viru
veev
wellcharacter
littl
known
human
antibodi
respons
veev
studi
use
phage
display
technolog
isol
panel
veevspecf
fab
two
human
donor
seven
four
fab
identifi
map
five
epitop
three
epitop
two
neutral
fab
isol
although
neutral
capac
lower
fab
express
complet
molecul
nativ
n
igg
neutralizationescap
veev
variant
nigg
isol
structur
gene
sequenc
determin
theoret
bind
site
base
sequenc
analysi
well
abil
neutral
four
neutralizationescap
variant
antiveev
murin
monoclon
antibodi
map
amino
acid
uniqu
neutral
domain
identifi
map
amino
acid
veev
human
epitop
map
wwwplosntdsorg
accord
manufactur
protocol
second
strand
cdna
synthes
accord
method
fulli
describ
patent
cdna
purifi
pcr
purif
kit
qiagen
singl
primer
amplif
perform
accord
method
fulli
describ
patent
amplifi
product
digest
xba
isac
kappa
light
chain
lc
xba
ika
lambda
lc
xho
iag
pin
ai
heavi
chain
hc
clone
fab
express
phagemid
vector
two
fab
librari
gener
donor
one
express
kappa
lc
one
lambda
lc
util
gamma
hc
fabbear
phage
librari
pan
one
four
round
enrich
inactiv
veev
coat
plate
overnight
well
wash
water
block
h
bovin
serum
albumin
bsa
phosphatebuff
salin
pb
phage
librari
ad
well
incub
h
well
wash
time
pb
contain
pbst
bound
fabphag
elut
glycin
ph
neutral
tri
base
use
infect
log
phase
e
coli
cell
strain
er
amplifi
ad
helper
phage
strain
infect
bacteria
round
pan
individu
coloni
produc
plate
infect
bacteria
screen
elisa
inactiv
veev
viru
perform
high
throughput
mode
use
tecan
robot
tecan
system
inc
san
jose
ca
larg
number
coloni
pick
use
qpix
instrument
genetix
inc
boston
individu
coloni
grown
overnight
deepwel
microtit
dish
higro
highspe
incubatorshak
genemachin
san
carlo
ca
aliquot
remov
store
stock
contain
glycerol
dmso
centrifug
deepwel
dish
fabcontain
supernat
collect
elisa
screen
alkalin
phosphatas
ap
label
goat
antihuman
fab
pierc
proteinthermo
fisher
scientif
rockford
il
use
detect
express
fab
bound
antigen
miniprep
dna
qiagen
posit
coloni
sequenc
across
light
heavi
chain
use
standard
primer
phagemid
express
vector
sequenc
analyz
use
dnastar
softwar
dnastar
inc
madison
wi
identifi
classifi
uniqu
candid
solubl
fab
express
purif
gene
iii
fusion
region
phagemid
remov
posit
uniqu
candid
subclon
stage
possibl
insert
oligonucleotid
encod
combin
epitop
tag
consist
influenza
viru
hemagglutinin
ha
tag
histidin
residu
tag
detect
purif
antiha
andor
ninta
pan
screen
addit
librari
done
inactiv
veev
either
without
epitop
mask
nonneutr
hmab
engin
e
igg
eigg
increas
chanc
isol
fab
neutral
capabl
pan
epitop
mask
well
coat
veev
incub
eigg
mgml
eigg
mg
ml
bsapb
min
follow
addit
librari
phage
incub
h
fab
select
character
clone
fab
express
vector
use
eco
risp
restrict
site
avail
vector
figur
two
fab
eco
ri
site
lc
clone
vector
contain
fab
lc
hc
use
xba
iag
site
figur
select
fab
produc
e
coli
cell
induct
isopropylbdthiogalactopyranosid
purifi
goat
antihuman
igg
f
affin
column
purifi
fab
use
posit
control
elisa
prepar
eigg
papain
digest
use
immunopur
fab
prepar
kit
pierc
accord
manufactur
instruct
four
hfab
convert
fulllength
twostep
clone
process
figur
region
lc
hc
xho
site
replac
mammalian
control
element
includ
poli
signal
end
lc
human
cytomegaloviru
promot
direct
express
hc
hc
mammalian
leader
sequenc
intermedi
insert
via
restrict
site
sfi
age
mammalian
express
vector
contain
addit
control
element
hc
constant
domain
result
engin
differ
n
sequenc
due
nonn
aa
codon
three
restrict
site
xba
sac
xho
present
nterminu
lc
hc
eigg
convert
igg
contain
n
sequenc
three
step
use
sitespecif
mutat
overlap
pcr
figur
sequenc
construct
verifi
hmab
produc
transfect
ml
cell
cellsml
mg
mab
express
vector
dna
use
effecten
qiagen
accord
manufactur
protocol
cultur
supernat
harvest
day
transfect
mab
purifi
protein
column
use
fplc
stabl
cell
line
produc
nigg
establish
select
transfect
cell
puromycin
ml
transfect
cell
initi
grown
plate
medium
screen
elisa
use
goat
antihuman
igg
f
antibodyap
conjug
jackson
immunoresearch
west
grove
pa
detect
well
highest
antibodi
express
chosen
singl
cell
select
four
plate
well
contain
singlecel
coloni
test
elisa
best
produc
chosen
expans
one
clone
grown
l
l
cultur
produc
mg
mg
mab
respect
protein
column
purif
purifi
antibodi
show
specif
bind
inactiv
veev
compar
nigg
prepar
transient
transfect
cell
genbank
access
number
nigg
light
heavi
chain
variabl
region
sequenc
respect
indirect
elisa
use
verifi
veev
bind
purifi
hfab
determin
crossreact
select
hfab
hmab
six
veev
subtyp
four
varieti
subtyp
elisa
perform
essenti
previous
describ
fab
mab
bind
purifi
viru
detect
goat
antihuman
igg
f
fcspecificap
conjug
jackson
immunoresearch
absorb
ratio
test
samplea
neg
control
consid
posit
competit
bind
assay
cba
use
determin
abil
nigg
block
bind
antiveev
neutral
mmabhorseradish
peroxidas
hrp
conjug
convers
abil
purifi
mmab
hfab
block
bind
nigghrp
viru
dilut
unconjug
mmab
hmab
hfab
result
approxim
bind
veev
determin
titrat
indirect
elisa
use
either
apconjug
goat
antimous
igg
fcspecif
goat
antihuman
igg
f
specif
detector
sigma
phosphatas
substrat
reaction
read
nm
dilut
mab
conjug
result
approxim
also
determin
use
cba
veev
human
epitop
map
wwwplosntdsorg
competit
use
mabhrp
conjug
well
coat
mg
veev
overnight
block
goat
serum
pb
h
mab
fab
competitor
ad
predetermin
dilut
serial
dilut
pbst
incub
room
temperatur
min
previous
determin
constant
dilut
mabhrp
block
buffer
ad
seriallydilut
competitor
incub
h
one
hundr
ml
premix
tetramethyl
benzidin
substrat
neogen
corp
lexington
ky
ad
well
reaction
stop
min
ml
h
plate
read
nm
viral
protein
specif
antibodi
determin
immunoblot
use
precast
trisglycin
gel
invitrogen
fraction
purifi
veev
mg
per
lane
reduc
nonreduc
condit
min
volt
electroblot
onto
mm
nitrocellulos
membran
use
novex
xcell
blot
apparatu
invitrogen
done
accord
manufactur
protocol
membran
block
startingblock
buffer
pierc
prevent
nonspecif
bind
membran
strip
incub
purifi
hmab
hfab
well
protein
mmab
h
room
temperatur
follow
incub
either
apconjug
goat
antihuman
igg
f
goat
antimous
igg
jackson
immunoresearch
h
visual
tetrazolium
phosphatas
substrat
kirkegaard
perri
laboratori
gaithersburg
md
prnt
igg
fab
antibodi
fragment
perform
essenti
previous
describ
neutralizationescap
variant
virus
select
nigg
use
infecti
clone
veev
manner
similar
use
previous
select
escap
variant
virus
neutral
mmab
case
differ
amount
purifi
mab
nigg
replic
mg
mg
mg
incub
approxim
pfu
viru
h
plate
vero
cell
monolay
plate
wellisol
plaqu
core
elut
overnight
ml
elut
viru
sampl
incub
mg
ml
nigg
h
sampl
adsorb
vero
cell
contain
mg
mabml
cultur
medium
monitor
cpe
supernat
collect
second
select
cycl
well
show
cpe
viru
seed
pass
vero
cell
without
addit
nigg
two
variant
virus
isol
rna
extract
aliquot
seed
viru
variant
parent
virus
use
qiaamp
viral
rna
kit
qiagen
follow
manufactur
instruct
rna
elut
ml
nucleasefre
water
store
amplim
sequenc
glycoproteincod
region
two
variant
virus
gener
standard
rtpcr
perform
either
ml
templat
rna
pmol
primer
tabl
mlreaction
use
titan
rtpcr
kit
roch
molecular
biochem
indianapoli
follow
manufactur
protocol
initi
rt
perform
min
follow
denatur
min
pcr
includ
cycl
sec
sec
min
cycl
sec
sec
final
extens
min
dna
engin
thermocycl
biorad
hercul
ca
result
amplim
gel
purifi
use
qiaquick
gel
extract
kit
qiagen
essenti
follow
manufactur
protocol
approxim
ng
amplim
use
direct
sequenc
use
fast
thermocycl
big
dye
autom
dna
sequenc
kit
genet
analyz
appli
biosystem
foster
citi
ca
bone
marrow
specimen
match
sera
donat
veev
seroposit
activ
servic
militari
personnel
provid
alexion
antibodi
technolog
aat
san
diego
ca
commerci
sourc
human
donor
sera
test
inactiv
veev
use
indirect
elisa
inactiv
veev
use
aat
nativ
inactiv
veev
use
dvbid
cdc
colorado
state
univers
fort
collin
co
two
donor
bone
marrow
select
use
construct
phage
display
librari
larg
librari
phage
particl
per
ml
obtain
pan
four
round
inactiv
veev
panel
hfab
clone
pan
round
three
four
four
librari
screen
veev
well
bsa
neg
control
three
hfab
clone
highest
elisa
signal
four
librari
select
sequenc
analysi
sequenc
result
shown
show
three
clone
ident
ten
clone
variabl
hc
region
major
fab
differ
lc
sequenc
uniqu
clone
three
separ
hc
group
four
hfab
clone
express
solubl
molecul
purifi
ninta
column
chromatographi
use
serolog
assay
four
clone
also
convert
fulllength
molecul
figur
clone
signific
veevneutr
abil
stabl
cell
line
express
nigg
gener
cell
attempt
made
identifi
addit
antiveev
hfab
use
librari
donor
case
veev
use
pan
screen
inactiv
bpl
previous
viru
use
procedur
inactiv
bpl
concentr
subsequ
shown
reduc
bind
eigg
nigg
tabl
pan
done
without
epitop
mask
nonneutr
hmab
eigg
eigg
order
increas
probabl
isol
fab
neutral
abil
nine
new
hfab
isol
four
use
epitop
mask
protocol
five
without
mask
hmab
titrat
veev
elisa
figur
three
hmab
mmab
similar
bind
affin
titer
approxim
ngml
hfab
endpoint
titer
ngml
except
titer
approxim
mgml
fig
viral
protein
specif
hmab
hfab
determin
immunoblot
use
purifi
veev
separ
page
reduc
nonreduc
condit
seven
antibodi
specif
glycoprotein
four
antibodi
recogn
reduc
nonreduc
protein
wherea
antibodi
lost
reactiv
protein
subject
reduc
condit
exposur
tabl
human
antibodi
evalu
elisa
determin
crossreact
nine
veev
repres
four
subtyp
varieti
well
subtyp
tabl
hmab
epitop
design
base
number
specif
veev
subtyp
varieti
recogn
antibodi
elisa
sequenc
data
mab
fab
hc
lc
complementari
determin
region
tabl
crossreact
analysi
also
present
graphic
form
sinc
antibodi
similar
crossreact
uniqu
titrat
curv
antibodi
concentr
plot
versu
absorb
nm
figur
suffici
amount
mab
eigg
eigg
avail
determin
elisa
crossreact
shown
specif
immunoblot
prnt
endpoint
data
shown
eigg
assign
epitop
crossreact
mab
character
react
veev
subtyp
varieti
test
except
subtyp
tabl
figur
mab
aa
sequenc
differ
sequenc
might
indic
mab
bind
differ
overlap
epitop
tabl
fab
assign
epitop
base
similar
elisa
titrat
curv
mab
figur
crossreact
tabl
differ
sequenc
tabl
gener
lower
level
reactiv
veev
subtyp
especi
subtyp
compar
eigg
higher
reactiv
level
eigg
compar
fab
could
due
fact
complet
igg
molecul
although
sequenc
b
fab
sequenc
complet
differ
tabl
three
b
fab
ident
sequenc
sequenc
similar
tabl
fab
sequenc
throughout
except
one
aa
chang
framework
region
ly
arg
addit
group
fab
distinct
reactiv
profil
consist
three
reactiv
group
curv
includ
follow
subtyp
varieti
figur
mab
nigg
uniqu
crossreact
pattern
uniqu
sequenc
well
potent
viral
neutral
activ
assign
epitop
c
tabl
figur
fab
isol
differ
bone
marrow
donor
also
uniqu
sequenc
uniqu
crossreact
pattern
assign
epitop
tabl
figur
hfab
isol
use
epitop
block
pan
process
block
two
nonneutr
mab
desir
effect
increas
isol
neutral
fab
instead
block
seem
inhibit
bind
fab
sinc
fab
isol
limit
neutral
abil
typic
mab
tabl
fab
ident
sequenc
similar
sequenc
two
aa
differ
fab
assign
epitop
tabl
figur
fab
crossreact
antibodi
identifi
show
good
reactiv
veev
subtyp
test
fab
uniqu
sequenc
well
crossreact
pattern
assign
epitop
b
c
respect
tabl
figur
cba
perform
elisa
use
veev
antigen
determin
spatial
overlap
epitop
c
defin
neutral
hmab
nigg
epitop
defin
hfab
homolog
fab
nigg
abl
compet
nigg
unconjug
conjug
hrp
tabl
none
b
b
c
fab
show
competit
nigg
cba
mmab
hmab
also
use
evalu
spatial
similar
c
epitop
defin
mab
nigg
previous
character
veev
epitop
defin
mmab
compris
major
neutral
domain
competit
valu
consid
signific
tabl
result
show
epitop
c
spatial
align
mmabdefin
epitop
f
antibodi
defin
epitop
show
reciproc
twoway
competit
oneway
competit
includ
nigg
compet
hrp
e
hrp
respect
howev
neither
e
could
compet
murin
human
c
mab
compet
respect
significantli
block
viru
bind
c
addit
competit
g
h
mmab
analys
indic
nigg
bind
epitop
within
major
neutral
domain
veev
glycoprotein
defin
mmab
antiveev
mmab
neutralizationescap
variant
mutat
epitop
c
f
g
h
evalu
reactiv
nigg
epitop
recogn
near
chang
aa
residu
neutralizationescap
variant
virus
would
unabl
neutral
variant
result
indic
abl
neutral
variant
virus
includ
specif
epitop
tabl
nigg
prnt
endpoint
equival
variant
virus
well
parent
veev
mab
nigg
use
select
neutralizationescap
variant
veev
infecti
clone
order
accur
map
bind
site
potent
neutral
antibodi
two
variant
v
virus
isol
requir
either
nigg
neutral
need
neutral
parent
veev
tabl
neutral
variant
also
evalu
human
igg
known
bind
c
epitop
viru
requir
igg
parent
viru
neutral
thu
neutralizationresist
nigg
igg
although
viru
resist
neutral
nigg
neutral
variant
well
neutral
veev
genom
variant
parent
virus
sequenc
nucleotid
includ
genet
inform
viral
structur
protein
portion
capsid
mutat
variant
virus
found
glycoprotein
aa
tabl
viru
transit
g
nucleotid
result
nonconserv
amino
acid
chang
ly
glu
also
delet
nucleotid
code
val
parent
viru
viru
silent
g
chang
nucleotid
follow
delet
nucleotid
code
ly
sequenc
chang
delet
neutralizationescap
variant
virus
indic
bind
site
glycoprotein
nigg
neutral
activ
somewhat
reduc
viru
suggest
delet
ly
disrupt
bind
ly
glu
substitut
coupl
val
delet
found
viru
humor
immun
respons
veev
infect
mice
well
character
antiveev
mmab
play
essenti
role
identifi
import
antigen
domain
viru
glycoprotein
although
nonhuman
primat
model
use
evalu
vaccin
efficaci
candid
veev
antibodi
repertoir
primat
human
well
character
use
phage
antibodi
librari
gener
immun
nonimmun
donor
prove
effici
method
obtain
divers
set
nonhuman
primat
human
antibodi
wide
varieti
virus
veev
human
papillomaviru
sin
nombr
viru
west
nile
viru
yellow
fever
viru
yfv
rabi
viru
sarscoronaviru
hepat
viru
hav
dengu
viru
rotaviru
hantaan
viru
measl
viru
hiv
studi
character
uniqu
hfab
hmab
viral
protein
specif
veev
subtyp
crossreact
viru
neutral
capac
construct
first
human
epitop
map
protein
alphaviru
addit
map
potenti
bind
site
potent
neutral
hmab
nigg
use
cba
hfab
well
antiveev
mmab
isol
sequenc
rna
code
glycoprotein
neutralizationescap
variant
virus
antibodi
clone
select
character
show
good
elisa
bind
veev
uniqu
complet
gene
sequenc
seven
hmab
specif
glycoprotein
four
two
neutral
hfab
isol
despit
use
block
strategi
pan
favor
select
antibodi
similar
strategi
use
without
much
success
attempt
favor
select
west
nile
viru
hmab
specif
domain
iii
envelop
glycoprotein
specif
nigg
prnt
endpoint
ngml
equival
describ
effect
neutral
antiveev
mmab
tabl
poorer
neutral
titer
human
chimpanze
fab
mab
specif
yfv
hav
report
mg
ml
mgml
mgml
respect
hfab
prnt
endpoint
mgml
lower
titer
might
higher
complet
igg
antibodi
typic
neutral
titer
mmab
less
mmab
high
degre
crossreact
variou
veev
subtyp
varieti
found
hmab
hfab
compar
spectrum
typespecif
subgroupreact
reactiv
shown
wellcharacter
mmab
tabl
fact
veev
typespecif
hmab
isol
methodolog
gener
mmab
differ
use
studi
studi
screen
done
platebound
purifi
viru
clone
select
highest
level
bind
elisa
viru
use
pan
studi
inactiv
either
bpl
live
viru
use
elisa
select
mmab
howev
bpltreat
viru
reactiv
neutral
mmab
elisa
assum
neutral
hmab
would
also
bind
antigen
hmab
nigg
origin
select
use
bpltreat
viru
later
discov
bind
live
viru
greater
tabl
therefor
amount
bpl
use
decreas
improv
bind
data
shown
fact
bind
mmab
affect
treat
viru
bpl
bind
hmab
affect
suggest
epitop
recogn
veev
neutral
mmab
hmab
may
elisa
bind
affin
three
human
igg
antibodi
veev
equival
mmab
figur
nigg
potent
neutral
mab
neither
eigg
biolog
activ
case
high
affin
necessarili
correl
neutral
capac
cba
analysi
indic
c
epitop
defin
nigg
spatial
overlap
epitop
defin
panel
hfab
tabl
crossreact
profil
hmab
also
uniqu
tabl
figur
cba
result
compar
panel
mmab
import
defin
major
veev
neutral
domain
suggest
epitop
f
spatial
near
epitop
c
base
reciproc
competit
pattern
tabl
f
epitop
map
residu
yet
map
howev
origin
descript
neutral
domain
defin
mmab
direct
competit
f
analysi
reveal
neutral
four
mmab
neutralizationescap
variant
virus
degre
parent
veev
indic
bind
affect
aa
chang
either
provid
import
evid
recogn
differ
epitop
four
neutral
mmab
use
gener
variant
virus
tabl
isol
two
neutralizationescap
variant
virus
nigg
sequenc
structur
protein
gene
locat
theoret
bind
site
hmab
base
aa
chang
variant
virus
bind
map
aa
residu
tabl
aa
delet
substitut
virus
alter
net
charg
degre
hydrophil
region
possibl
affect
access
epitop
antibodi
bind
variant
viru
resist
neutral
although
variant
virus
requir
significantli
mab
neutral
requir
veev
tabl
also
test
whether
human
mmab
igg
specif
c
epitop
could
neutral
two
variant
virus
bind
site
differ
would
expect
would
neutral
variant
virus
howev
neutral
resist
neutral
rather
puzzl
result
addit
reciproc
competit
f
mmab
might
suggest
type
interact
induc
conform
chang
neutral
domain
locat
cours
possibl
exclud
detect
mutat
contact
residu
amino
acid
substitut
delet
induc
distant
conform
chang
affect
mab
bind
identif
novel
neutral
domain
veev
glycoprotein
analog
identif
second
neutral
domain
sv
identifi
use
mab
neutralizationescap
variant
virus
contain
code
chang
either
propos
residu
form
altern
neutral
site
could
fold
form
bind
site
surfac
dimens
approxim
measur
similar
determin
interact
lysozymeantilysozym
immun
complex
transposoninsert
mutagenesi
sv
result
viru
insert
less
effici
neutral
sv
mmab
similarli
variant
rrv
attenu
mice
five
aa
differ
compar
wildtyp
posit
residu
lie
major
neutral
domain
wherea
residu
propos
influenc
neutral
effici
variant
viru
examin
veev
mutat
affect
viru
bind
heparan
sulfat
led
propos
residu
may
form
conform
surfaceaccess
epitop
involv
viru
neutral
unknown
although
crystal
structur
alphaviru
glycoprotein
solv
cryoem
reconstruct
report
resolut
cryoem
map
sv
present
mukhopadhyay
et
al
annot
marker
repres
locat
glycosyl
site
protein
nterminu
neutral
fab
bind
site
adapt
figur
show
probabl
surfaceaccess
locat
hmab
nigg
bind
site
relationship
marker
figur
b
map
epitop
uniqu
neutral
site
base
data
present
studi
epitop
bind
hmab
nigg
sensit
bpl
treatment
epitop
recogn
neutral
mmab
hmab
abl
neutral
antiveev
mmab
neutral
escap
variant
virus
therefor
bind
residu
defin
critic
neutral
domain
hmab
neutral
escap
variant
virus
defin
neutral
epitop
involv
result
studi
mice
use
veev
synthet
peptid
vaccin
includ
propos
map
ectodomain
complement
placement
c
epitop
figur
previous
identifi
two
peptid
vaccin
protect
mice
virul
veev
challeng
also
isol
antipeptid
mab
specif
passiv
protect
mice
challeng
veev
varieti
none
antipeptid
antibodi
either
polyclon
monoclon
virusneutr
activ
indic
cognat
peptid
like
surfaceaccess
lack
appropri
conform
propos
configur
molecul
shown
fig
place
c
epitop
surfac
spike
cryptic
locat
nterminu
aa
arrang
would
agreement
current
knowledg
structur
glycoprotein
locat
specif
marker
function
attribut
specifi
epitop
collabor
obtain
structur
data
fabvirion
complex
determin
actual
bind
site
nigg
human
murin
mab
veev
neutral
abil
hmab
nigg
similar
exhibit
human
mmab
igg
administ
prophylact
littl
ng
abl
protect
mice
challeng
intraperiton
virul
veev
addit
given
one
h
veev
infect
cure
infect
mice
respect
nigg
would
expect
effect
immunotherapeut
igg
administr
cocktail
two
mab
bind
differ
epitop
could
provid
increas
protect
gener
virul
veev
neutralizationescap
variant
vivo
figur
schemat
present
convers
fab
engin
igg
eigg
fragment
contain
mammalian
control
element
insert
fab
xho
site
fab
vector
sfi
age
fragment
contain
light
chain
mammalian
control
element
heavi
chain
transfer
igg
express
vector
contain
mammalian
element
upstream
light
chain
well
igg
hing
region
downstream
heavi
chain
final
construct
eigg
retain
engin
xba
sac
xho
site
found
mb
ppt
figur
convers
engin
e
eig
nativ
n
nigg
convers
done
step
process
hind
iii
mammalian
control
element
heavi
chain
chang
asc
sitespecif
mutagenesi
overlap
pcr
xba
sac
site
light
chain
xho
site
heavi
chain
convert
nativ
sequenc
sitespecif
mutagenesi
overlap
pcr
